Highlights from recent Life Science venture capital news.
May 01, 2012 – San Francisco, CA
Castlight Health Secures $100 Million in Series D Funding
Castlight Health, the leading provider of health care transparency solutions, today announced it has secured $100 million in Series D funding. With this investment, the company will aggressively capitalize on growing customer demand for health care transparency solutions that improve the quality of health care and deliver savings to customers and users. The round brings Castlight Health’s total funding to $181 million and includes participation from two major unnamed mutual funds, as well as T. Rowe Price, Redmile Group and previous investors.
May 04, 2012 – Ft. Lauderdale, FL
OrthoSensor Secures an Additional $15M in Series B Financing
OrthoSensor, Inc., the leader in intelligent orthopedics, announced that the company has closed on an additional $15 million in Series B Preferred Stock financing, bringing the total Series B investment to $36 million. The funds will be used to expand the commercialization of the company’s first product, the OrthoSensor™ Knee Balancer, and to support the launch of OrthoSensor’s line of additional intelligent orthopedic devices.
April 30, 2012 – Houston, TX
OrthoAccel Announces $10 Million USD Equity Investment
OrthoAccel Technologies, Inc. (“OrthoAccel” or “the Company”) today announced an investment of $10 million in growth capital to fund the US launch of its AcceleDentTM system and ongoing working capital needs. The investment was led by HealthpointCapital Partners (“HealthpointCapital”), with existing investor S3 Ventures (“S3”) also participating. In conjunction with the financing, HealthpointCapital’s John McCormick will join the company’s board of directors. Brian R. Smith from S3 Ventures will remain on the board.
Secondary Venture Round
May 3, 2012 – Oxford, UK
Oxford Nanopore announces £31.4 million ($50.8 million) fundraising
Oxford Nanopore Technologies Ltd, a privately held company that is developing a disruptive technology for the real-time electronic analysis of single molecules, today announced that it has raised £31.4 million ($50.8 million) in new funding via a private placement of ordinary shares in the Company. This round of funding, nearly all of which comes from existing investors, will support a range of corporate development activities.
This Week In Venture Capital is brought to you by VM Index from Venture Market Intelligence – Venture Capital made easier
VM Index is an online Life Science, Med Tech & Biotech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.